Compare Kroger Co (KR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs ResMed Inc. — how do they compare? Kroger Co trades at $57.26 (market cap $35.75B), while ResMed Inc. trades at $195.48 (market cap $28.81B). The key difference: Kroger Co is the larger of the two by market cap, and Kroger Co pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| KR | RMD | |
|---|---|---|
Market Cap | $35.75B | $28.81B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $293.73 |
52-Week Low | $55.53 | $182.82 |
Enterprise Value | $55.85B | $27.99B |
Dividend Yield | 2.47% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $58.39, down 0.73% on the day, with a bearish technical signal and mixed earnings history. The company maintains stable revenue near $147 billion (2025) and recently announced a $1.65 billion acquisition of Giant Eagle (Reuters, July 1, 2026). Cash flow from operations remains strong at $5.79 billion, though net income margin is thin at 0.71%.
Outlook: KR offers value with low P/S (0.25) and dividend yield, but faces margin pressure and integration risks from acquisitions. Analyst consensus is bullish with a $68.63 price target, though technical weakness and competitive threats warrant caution for near-term volatility.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
